Oramed Pharmaceuticals Inc.
ORMP· Nasdaq
ORMPOramed Pharmaceuticals Inc.
Filed Apr 11, 2013 · 10-Q · 42 days after period end · 0001178913-13-001073
| Metric | Q2 2013 | Q2 2012 | Q2 2011 |
|---|---|---|---|
| Net Income | -$1.23M | -$985.38K | -$642.79K |
| EPS Diluted | -$0.17 | $0.17 | $0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
ended Feb 28, 2013 · filed Apr 11, 2013 · 42 d after period end
